Nathwani, Nitya
Bell, Jill
Cherepanov, Dasha
Sowell, France Ginchereau
Shah, Rachel
McCarrier, Kelly
Hari, Parameswaran
Funding for this research was provided by:
Takeda Pharmaceutical Company
Article History
Received: 13 August 2021
Accepted: 10 March 2022
First Online: 1 April 2022
Declarations
:
: The study protocol was approved by Advarra IRB (Columbia, MD). The study was conducted in line with the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all participants included in the study.
: Written informed consent was obtained from all participants included in the study.
: NN has no conflicts of interest to disclose. JB and DC were employees of Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA, at the time this research was conducted. PH has received honoraria for consulting from Takeda, BMS, Amgen, Karyopharm, Janssen, and Sanofi. FGS, RS, and KM were employees of Pharmerit – an OPEN Health Company, at the time the research was conducted.